Evidence map›Paper›PMID 37884352›Full record

ArticleGut2024

IL-20 controls resolution of experimental colitis by regulating epithelial IFN/STAT2 signalling.

Mircea Teodor Chiriac, Zsuzsanna Hracsko, Claudia Günther, Miguel Gonzalez-Acera, Raja Atreya, Iris Stolzer, Leonie Wittner, Anja Dressel, Laura Schickedanz, Reyes Gamez-Belmonte and 16 more

Open access · hybridAbstract read
In one paragraph

Article in Gut, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. RNF168 promotes chronic colitis through ANXA7-mediated autophagy and NLRP3-driven pyroptosis.Apoptosis : an international journal on programmed cell death · 2026
    Article
  7. Article
  8. Review
  9. Review
  10. Roles of Deubiquitinases OTUD3 and OTUD5 in Inflammatory Bowel Diseases.International journal of molecular sciences · 2025
    Review
  11. Article
  12. Review
  13. Article
  14. Dihydroartemisinin Modulates Enteric Glial Cell Heterogeneity to Alleviate Colitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 7 institutions in 3 countries.

Mircea Teodor ChiriacDepartment of Medicine 1, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany mircea.chiriac@uk-erlangen.de.ORCID 0000-0002-9990-7862
Zsuzsanna HracskoDepartment of Medicine 1, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Claudia GüntherDepartment of Medicine 1, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.ORCID 0000-0001-8360-3525
Miguel Gonzalez-AceraDepartment of Medicine 1, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Raja AtreyaDeutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0002-8556-8433
Iris StolzerDepartment of Medicine 1, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Leonie WittnerDepartment of Medicine 1, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Anja DresselDepartment of Medicine 1, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Laura SchickedanzDepartment of Medicine 1, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Reyes Gamez-BelmonteDepartment of Medicine 1, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Lena ErkertDepartment of Medicine 1, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Gheorghe HundorfeanDepartment of Medicine 1, Gastroenterology, Endocrinology and Pneumology, and the Ludwig Demling Endoscopy Center of Excellence, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Sebastian ZundlerDepartment of Medicine 1, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.ORCID 0000-0003-0888-2784
Timo RathDepartment of Medicine 1, Gastroenterology, Endocrinology and Pneumology, and the Ludwig Demling Endoscopy Center of Excellence, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Stefania VetranoIBD Center, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Italy.
Silvio DaneseDepartment of Gastroenterology and Digestive Endoscopy & Division of Immunology, Transplantation and Infectious Disease, IRCCS Ospedale San Raffaele, Milano, Italy.
Gregor SturmMedical University of Innsbruck, Biocenter, Institute of Bioinformatics, Innsbruck, Austria.
Zlatko TrajanoskiMedical University of Innsbruck, Biocenter, Institute of Bioinformatics, Innsbruck, Austria.
Anja A KühliPATH.Berlin, Core Unit of Charité, Campus Benjamin Franklin, Charite Universitatsmedizin Berlin, Berlin, Germany.
Britta SiegmundCorporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medical Department, Division of Gastroenterology, Infectious Diseases and Rheumatology, Campus Benjamin Franklin, Charite Universitatsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-0055-958X
Arndt HartmannInstitute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Stefan WirtzDepartment of Medicine 1, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Jürgen SieblerDeutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Erlangen, Germany.
Susetta FinottoDeutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Erlangen, Germany.
Christoph BeckerDepartment of Medicine 1, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.ORCID 0000-0002-1388-1041
Markus F NeurathDeutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Erlangen, Germany.ORCID 0000-0003-4344-1474
Universitätsklinikum Erlangen · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEInnsbruck Medical University · ATCharité - Universitätsmedizin Berlin · DEHumanitas University · ITHumboldt-Universität zu Berlin · DEVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe sought to investigate the role of interleukin (IL)-20 in IBD and experimental colitis.

designExperimental colitis was induced in mice deficient in components of the IL-20 and signal transducer and activator of transcription (STAT)2 signalling pathways. In vivo imaging, high-resolution mini-endoscopy and histology were used to assess intestinal inflammation. We further used RNA-sequencing (RNA-Seq), RNAScope and Gene Ontology analysis, western blot analysis and co-immunoprecipitation, confocal microscopy and intestinal epithelial cell (IEC)-derived three-dimensional organoids to investigate the underlying molecular mechanisms. Results were validated using samples from patients with IBD and non-IBD control subjects by a combination of RNA-Seq, organoids and immunostainings.

resultsIn IBD,

conclusionIL-20 controls colitis and mucosal healing by interfering with the IFN/STAT2 death signalling pathway in IECs. These results indicate new directions for suppressing gut inflammation by modulating IL-20-controlled STAT2 signals.

Indexed as

ColitisInflammatory Bowel DiseasesAnimalsDextran SulfateEpithelial CellsHumansInflammationInterleukinsIntestinal MucosaMiceMice, Inbred C57BLSTAT2 Transcription FactorDextran Sulfateinterleukin 20InterleukinsSTAT2 protein, humanSTAT2 Transcription Factorexperimental colitisinflammatory bowel diseaseinterferoninterleukinssignal transduction

Identifiers

PMID37884352
PMCPMC10850655
OpenAlexW4387965661

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.